期刊
CANCER DISCOVERY
卷 3, 期 6, 页码 674-689出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2159-8290.CD-13-0081
关键词
-
类别
资金
- Genentech
- NIH [P50 NS057531, F30 CA171547, P30-CA77598, P50-CA101955, KL2-RR033182]
- Children's Tumor Foundation
- Zachary NF Fund
- Jacqueline Dunlap NF Fund
- Children's Tumor Foundation Young Investigators Award [2011-01-018]
- National Cancer Institute Training Grant [5T32CA059268-15]
- NIH MSTP grant [T32 GM008244]
- University of Minnesota Academic Health Center
Genetic changes required for the formation and progression of human Schwann cell tumors remain elusive. Using a Sleeping Beauty forward genetic screen, we identified several genes involved in canonical Wnt signaling as potential drivers of benign neurofibromas and malignant peripheral nerve sheath tumors (MPNSTs). In human neurofibromas and MPNSTs, activation of Wnt signaling increased with tumor grade and was associated with downregulation of beta-catenin destruction complex members or overexpression of a ligand that potentiates Wnt signaling, R-spondin 2 (RSPO2). Induction of Wnt signaling was sufficient to induce transformed properties in immortalized human Schwann cells, and downregulation of this pathway was sufficient to reduce the tumorigenic phenotype of human MPNST cell lines. Small-molecule inhibition of Wnt signaling effectively reduced the viability of MPNST cell lines and synergistically induced apoptosis when combined with an mTOR inhibitor, RAD-001, suggesting that Wnt inhibition represents a novel target for therapeutic intervention in Schwann cell tumors. SIGNIFICANCE: We show canonical Wnt/beta-catenin signaling is a novel genetic driver of Schwann cell tumor development and progression, due to downregulation of beta-catenin destruction complex members and overexpression of RSPO2. Inhibitors of Wnt signaling alone, or in combination with RAD-001, may have therapeutic value for patients with MPNSTs or neurofibromas. (c) 2013 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据